Preferred Label : Genetically Engineered Lymphocyte Therapy;
Origin ID : C64895;
UMLS CUI : C1880949;
Semantic type(s)
- concept_is_in_subset
https://www.has-sante.fr/portail/jcms/c_2899636/fr/zalmoxis
https://www.has-sante.fr/portail/jcms/c_2899636/fr/zalmoxis-lymphocytes-t-genetiquement-modifies-antineoplasique
2019
false
false
false
France
French
treatment outcome
orphan drug production
hematopoietic stem cell transplantation
t-lymphocytes
t-lymphocytes
Genetically Engineered Lymphocyte Therapy
hematologic neoplasms
adult
tissue donors
infusions, intravenous
graft vs host disease
transplantation, homologous
evaluation of the transparency committee
guidelines for drug use
---
Zalmoxis allogeneic T cells genetically modified with a retroviral vector encoding
for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR)
and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
https://www.ema.europa.eu/medicines/human/EPAR/Zalmoxis
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
drug approval
europe
risk assessment
hematopoietic stem cell transplantation
continuity of patient care
drug monitoring
t-lymphocytes
t-lymphocytes
Genetically Engineered Lymphocyte Therapy
hematologic neoplasms
adult
tissue donors
infusions, intravenous
graft vs host disease
product surveillance, postmarketing
transplantation, homologous
pregnancy
breast feeding
---
